Efferocytosis: another function of uPAR.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

1. Phagocytosis of Necrotic Debris at Sites of Injury and Inflammation.Frontiers in immunology · 2019
   Review
2. High molecular weight kininogen binds phosphatidylserine and opsonizes urokinase plasminogen activator receptor-mediated efferocytosis.Journal of immunology (Baltimore, Md. : 1950) · 2014
   Article
3. Extracellular histones inhibit efferocytosis.Molecular medicine (Cambridge, Mass.) · 2012
   Article
4. Role of the urokinase plasminogen activator receptor in mediating impaired efferocytosis of anti-SSA/Ro-bound apoptotic cardiocytes: Implications in the pathogenesis of congenital heart block.Circulation research · 2010
   Article

Corrections and comments

• Comment on
  Participation of the urokinase receptor in neutrophil efferocytosis.2009

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract